Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
SARS-CoV-2 mutations 'do not increase transmissibility'
Thurs November 26th - None of the SARS-CoV-2 virus mutations that have been documented so far increase transmissibility in humans, a new study has shown. More
Midlife high blood pressure linked to elderly brain damage
Thurs November 26th - High blood pressure in middle age is associated with the development of more extensive brain damage when elderly, researchers report today. More
Activity can offset sedentary lifestyle - WHO says
Thurs November 26th - Exceeding the recommendations for weekly physical activity can offset the health harms associated with prolonged sitting, says new guidelines from the World Health Organisation. More
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 04/08/2020 VICKY P ADAM wrote:
I would like to thank WORLD HERBS CLINIC for reve... on Medieval remedy for bacterial ...
On 29/07/2020 Amdre wrote:
When i read many blogs online about cure to HSV, a... on Medieval remedy for bacterial ...
On 14/07/2020 margret wrote:
I was diagnosed of ALS (amyotrophic lateral sclero... on Heart abnormalities revealed i...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...

Lowering androgen may protect against Covid-19

Thursday May 7th, 2020

Androgen-deprivation therapy given for prostate cancer may be protective against Covid-19 for these patients, researchers say today.

The virus partially depends on an androgen-regulated gene, TMPRSS2, which encourages tumour progression in prostate cancer.

Certain androgen-deprivation therapies reduce levels of TMPRSS2, so Professor Andrea Alimonti and her team at the Universita della Svizzera Italiana, Switzerland, investigated whether androgen-deprivation therapies can protect patients from Covid-19 infection.

The study is published in Annals of Oncology today (7 May). The team used information on 4,532 men in the Veneto region of Italy, and found that prostate cancer patients on androgen-deprivation therapies had a four-fold reduced risk of Covid-19 infection compared with patients who did not receive this therapy. Also, if they did become infected, the virus was less severe.

The researchers discovered that overall, male cancer patients had a 1.8-fold increased risk of Covid-19 infection compared with the general male population.

But among prostate cancer patients on androgen-deprivation therapy, fewer than expected developed Covid-19 infection and none of them died.

“Patients with prostate cancer receiving androgen-deprivation therapies had a significant four-fold reduced risk of Covid-19 infections compared to patients who did not receive androgen-deprivation therapy,” said Professor Alimonti.

“An even greater difference was found when we compared prostate cancer patients receiving androgen-deprivation therapy to patients with any other type of cancer; there was a more than five-fold reduction in risk of infection among the prostate cancer patients on androgen-deprivation therapy.

Editor-in-chief of Annals of Oncology, Professor Fabrice Andre, said: “The study does not provide a definitive conclusion about the role of androgen-deprivation therapy in patients infected with Covid-19, and this class of drugs should not be used for this purpose until prospective trials have confirmed its efficacy.”

Montopoli, M. et al. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (n=4532). Annals of Oncology 7 May 2020; doi: 10.1016/j.annonc.2020.04.479

Tags: Cancer | Europe | Men's Health | Pharmaceuticals | Respiratory

Printer friendly page Printer friendly page

Comment on this article:

<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)